Howie and Harlan are joined by Atheendar Venkataramani, a physician, health economist, and director of the Perelman School of Medicine’s Opportunity for Health Lab, to discuss the powerful role of economic opportunity in population health outcomes. Harlan reports on two studies where treatments’ unexpected benefits leapt ahead of understanding why they work. Howie reflects on the business model of the pharma industry and the market reaction to anti-obesity drugs.

Links:

Opportunity for Health | Home

“College Affirmative Action Bans and Smoking and Alcohol Use among Underrepresented Minority Adolescents in the United States: A Difference-in-differences Study”

“Police Killings and Their Spillover Effects on the Mental Health of Black Americans: A Population-based, Quasi-experimental Study”

“Officer-Involved Killings of Unarmed Black People and Racial Disparities in Sleep Health“

Behavioral Risk Factor Surveillance System | Home

“Building Black Wealth — The Role of Health Systems in Closing the Gap“

KFF | Understanding Mergers Between Hospitals and Health Systems in Different Markets

“In Hospitals, Affordable Housing Gets the Long-Term Investor It Needs”

American College of Cardiology 73rd Annual Scientific Session & Expo 

“Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes“

“Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial”

“A Placebo-Controlled Trial of PCI for Stable Angina“

“Trial of Lixisenatide in Early Parkinson’s Disease“

“The Cream of The Crop: 5 Biotechs That Outrank Most Stocks”

“How High Can Eli Lilly Stock Go? $1,000 A Share, One Analyst Says”

Learn more about the MBA for Executives program at Yale SOM.

Email Howie and Harlan comments or questions.